CureVac, a biotechnology firm based in Germany, announced on Tuesday that it will abandon its first-generation COVID-19 vaccine candidate in favour of cooperating with GSK to develop second-generation mRNA vaccine technology.

CureVac's Competitors, Revenue, Number of Employees, Funding, Acquisitions  & News - Owler Company Profile

Due to a potential overlap with approval deadlines for a second-generation candidate, the business announced it will withdraw its first-generation vaccine candidate CVnCoV, which failed late-stage studies with 47 % accuracy in June.

CVnCoV might have been approved as early as the second quarter of 2022, when candidates from the second-generation vaccine programme are scheduled to reach late-stage clinical development, according to CureVac.